Open AccessTirosine Kinase Inhibitors Adverse Events
Author(s) -
Campiotti Leonardo,
Maresca Andrea,
Guasti Luigina,
Grandi Anna Maria
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0397
Subject(s) - medicine , dasatinib , tyrosine kinase , adverse effect , tyrosine kinase inhibitor , proto oncogene tyrosine protein kinase src , pharmacology , cancer , receptor
The authors discuss dasatinib as a tyrosine kinase inhibitor with cardiovascular toxicity, which Lenihan and Kowey did not include in their article “Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors.”